MedPath

Platelet Reactivity With Fentanyl, Morphine, or no Narcotic

Phase 2
Terminated
Conditions
Platelet Reactivity
Fentanyl
Interventions
Registration Number
NCT05367336
Lead Sponsor
Spectrum Health - Lakeland
Brief Summary

The goal is to determine whether fentanyl and morphine have similar effects in reducing aspirin's effect upon platelets in emergency department patients with chest discomfort. Morphine has been shown to worsen outcomes in heart attack patients due to reduction of oral anti-platelet agent effectiveness and so many providers have switches to using fentanyl. However, it is largely unknown whether fentanyl has similar effects.

Detailed Description

Patients presenting to the emergency department with chest discomfort who are being administered aspirin will be offered enrollment in this study. At the time of their zero and two hour troponin we will also draw platelet aggregration studies to determine the effects of aspirin upon platelets. Narcotic medicines slow the absorption of aspirin. Morphine has therefore been shown to decrease the effectiveness of aspirin. Many providers therefore use fentanyl instead, however little is known about the effects of fentanyl upon aspirin. We will therefore compare the platelet reactivity of patients receiving morphine, fentanyl, or no narcotics

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • Adult Emergency Department patients undergoing 0 and 2 hour troponin testing
  • administered aspirin within 30 minutes of the initial blood draw.
  • patient presented via private vehicle
  • provide informed consent
  • over the age of 18
Exclusion Criteria
  • Patients not expected to get a 2 hour troponin;
  • patients already on aspirin, clopidogrel, or stronger anti-coagulants;
  • patients who arrived via EMS (Emergency Medical Services) given it can be difficult to find the run reports to determine whether patient received fentanyl in the pre-hospital period;
  • pregnant patients;
  • patients on chronic narcotics;
  • patients already once enrolled in this study,
  • inability to provide consent in English

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
FentanylFentanylthe 3rd group will be those receiving fentanyl
MorphineMorphinethe second group will be those receiving morphine
Primary Outcome Measures
NameTimeMethod
Baseline Arachidonic Acid Maximum Aggregation (%) ResultBaseline

Arachidonic Acid Maximum Aggregation is assessed using light transmission aggregometry (LTA). This method involves adding arachidonic acid to platelet-rich plasma (PRP) and measuring the change in light transmittance as platelets aggregate. The maximum aggregation percentage is recorded as the highest point of aggregation observed during the test. From a clinical perspective, normal aggregation is considered 70% or higher and values below 70% may indicate platelet dysfunction or the influence of antiplatelet medications such as aspirin. In this study, the control group is expected to show a significant decrease in Arachidonic Acid Maximum Aggregation (%) from the baseline to the 2-hour mark. However, this decrease is anticipated to be smaller in the groups receiving morphine and fentanyl.

2 Hour Arachidonic Acid Maximum Aggregation (%) Result2 hours

Arachidonic Acid Maximum Aggregation is assessed using light transmission aggregometry (LTA). This method involves adding arachidonic acid to platelet-rich plasma (PRP) and measuring the change in light transmittance as platelets aggregate. The maximum aggregation percentage is recorded as the highest point of aggregation observed during the test. From a clinical perspective, normal aggregation is considered 70% or higher and values below 70% may indicate platelet dysfunction or the influence of antiplatelet medications such as aspirin. In this study, the control group is expected to show a significant decrease in Arachidonic Acid Maximum Aggregation (%) from the baseline to the 2-hour mark. However, this decrease is anticipated to be smaller in the groups receiving morphine and fentanyl.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Spectrum Health Lakeland

🇺🇸

Saint Joseph, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath